Nystatin prophylaxis in immunocompromised children.

In conclusion, the use of nystatin for fungal prophylaxis in hematology/oncology/bone marrow transplantation patients appears to convey little or no benefit over no therapy. Nystatin treatment significantly reduced the frequency of multiple-site colonization and of persistently positive oropharyngeal cultures, but was not able to prevent the occurrence of disseminated fungal infections. Other antifungal agents (e.g., ketoconazole, fluconazole, itraconazole, oral or intravenous amphotericin B) may be of benefit. Studies comparing nystatin with other agents are available in the literature but are beyond the scope of this review.
AuthorsT L Taylor
JournalThe Annals of pharmacotherapy (Ann Pharmacother) Vol. 30 Issue 5 Pg. 534-5 (May 1996) ISSN: 1060-0280 [Print] UNITED STATES
PMID8740337 (Publication Type: Journal Article, Review)
Chemical References
  • Antifungal Agents
  • Nystatin
  • Agranulocytosis (complications)
  • Antifungal Agents (therapeutic use)
  • Bone Marrow Transplantation (adverse effects)
  • Candidiasis (etiology, prevention & control)
  • Child
  • Humans
  • Immunocompromised Host
  • Leukemia (complications)
  • Nystatin (therapeutic use)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!

Choose Username:
Verify Password: